↓ Skip to main content

Cochrane Database of Systematic Reviews

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

Overview of attention for article published in Cochrane database of systematic reviews, August 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
twitter
4 X users
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
101 Dimensions

Readers on

mendeley
172 Mendeley
Title
Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma
Published in
Cochrane database of systematic reviews, August 2012
DOI 10.1002/14651858.cd003915.pub4
Pubmed ID
Authors

Claire L Vale, Jayne Tierney, Sarah J Bull, Paul R Symonds

Abstract

Although endometrial adenocarcinoma is a common gynaecological cancer, a comparatively small proportion of patients present with, or develop, recurrent or advanced disease. However, for those women whose disease does progress or recur the prognosis is poor and the best treatment is yet to be identified. Co-morbidity, including obesity and cardiac disease, and concerns over toxicity have prevented more extensive studies of cytotoxic chemotherapy, although there are a number of active agents.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 172 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Brazil 1 <1%
Unknown 170 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 30 17%
Researcher 26 15%
Student > Bachelor 17 10%
Other 14 8%
Student > Ph. D. Student 10 6%
Other 32 19%
Unknown 43 25%
Readers by discipline Count As %
Medicine and Dentistry 68 40%
Nursing and Health Professions 13 8%
Biochemistry, Genetics and Molecular Biology 9 5%
Pharmacology, Toxicology and Pharmaceutical Science 8 5%
Psychology 6 3%
Other 20 12%
Unknown 48 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2022.
All research outputs
#4,659,519
of 25,373,627 outputs
Outputs from Cochrane database of systematic reviews
#6,804
of 11,484 outputs
Outputs of similar age
#32,441
of 186,054 outputs
Outputs of similar age from Cochrane database of systematic reviews
#114
of 204 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,484 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.9. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,054 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 204 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.